Sign In

Tuesday, April 24, 2018 - 3:00pm to 4:00pm
Add to Calendar

Content Contributor

NAFLD SIG

Presenter(s)

Monica Konerman, MD MSc
Michelle Long, MD

Moderator(s)

Rohit Loomba, MD, MHSc

Details

In this webinar, we will review the role of diet and exercise in the management of NAFLD. Specifically, we will overview the data in support of specific nutritional programs and physical activity regimens that have been shown to improve histologic components of NAFLD and NASH. Lastly, we will outline the remaining knowledge gaps and barriers related to lifestyle interventions in the treatment of NAFLD / NASH.

Presenter Bios

Monica Konerman, MD MSc

Dr. Monica Konerman is a Clinical Lecturer in Internal Medicine in the Division of Gastroenterology and Hepatology at the University of Michigan.

She is board certified in Transplant Hepatology and conducts clinical and health services research. Her areas of interest include NAFLD / NASH, liver transplant, and clinical risk prediction.

 

Michelle Long, MD

Dr. Long is an Assistant Professor of Medicine at the Boston University School of Medicine in Boston Massachusetts and an investigator at the Framingham Heart Study.

Dr. Long is hepatologist and physician scientist with a clinical specialization in non-alcoholic fatty liver disease (NAFLD). Her primary research focus is in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD.

Moderator Bio

Rohit Loomba, MD, MHSc

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.